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Abstract. The objective of this study was to formulate and evaluate a 
novel drug solubilization platform (so called nanosuspension prepared 
by comminution method using High pressure homogenizer; GEA Niro 
soavi) and further use the nanosuspension as granulating fluid admixed 
with excipients for further tablet production. The solid state characteri-
zation of Lacidipine along with the excipients   reveal compatibility , as 
confirmed X-ray diffraction (XRD), Fourier transform infrared spectros-
copy (FTIR) and Differential scanning calorimetry (DSC). The perfor-
mance of nanosuspension is highly dependent on the selection of poly-
mer stabilizer; hence different polymers such as hydroxy propyl cellu-
lose, propylene glycol and poly vinyl pyrrolidone were used in the study 
and evaluated. The results revealed hydroxy propyl cellulose as a suita-
ble stabilizer compared to others polymer. The dissolution studies of 
Lacidipine shows complete release of drug within 45 minutes using 
hydroxy propyl cellulose as stabilizer in comparison to  available mar-
keted product. Hydroxy propyl cellulose was better adsorbed with the 
drug compared to other polymers resulting in better mechanical inter-
action during comminution which causes the drug particle size to reach 
in nano meter scale. The particle size of the nanosuspension, as con-
firmed by Zeta revealed a particle size of 293.7 nm. The appearance of 
the nanosuspension shows a bluish opalescence and the morphology 
revealed by Transmission Electron Microscope shows a particle size of 
200.0 nm.  The In-Vivo pharmacokinetic study was performed on rab-
bits to assess the bioavailability, since the bioavailability is directly 
proportional to the particle size. The In Vivo pharmacokinetic results 
revealed that the AUC and Cmax were increased to two and six folds 
respectively in comparison to conventional market tablet. This may be 
recognized to increase solubility and permeability of the drug due to 
this novel formulation approach.  
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Instroduction. The objective of the study was to formulate and evaluate 
BCS class IV cardiovascular drug Lacidipine by nano sized drug suspen-
sion. Lacidipine has low solubility in almost all the solvents. Lacidipine 
belongs to 1,4-dihydropyridine derivatives which are characterized by 
very poor solubility and low dissolution rate in water. The drug delivery 
of Lacidipine in new drug delivery form is essential to overcome the low 
solubility and improve the bioavailability. Several techniques and ap-
proaches were commonly used to increase the solubility and bioavailabil-
ity of Lacidipine such as micro emulsion based transdermal gels as report-
ed by Gannu R. et al. [1], solid dispersion technique using PVP K 29/32 as 
reported by Amit Mukharya et al. [2]. Nanosuspension is a novel formula-
tion approach to deliver the drug in nanometer range. The nanosuspen-
sion is a unique technique which controls both physic and chemical char-
acteristics of a drug as suggested by Chee Wun How et.al [3], Adamson 
and Gast et.al [4], suggests one need to increase the change of  Gibbs 
free energy  ( ∆ G) , so as to achieve the objective of reducing the critical 
size and surface energy perquisite for the development of nano particle. 
Nanosuspensions are simple, cost effective as reported by Constantinides 
et al. [5]. The process is feasible in industrial pharmaceutical unit opera-
tion. The drug delivery of Lacidipine by nano particles using comminution 
is an efficient way to overcome the limitation of convectional drug deliv-
ery of Lacidipine tablets.  Nanosuspension is sensitive to the choice of 
polymers as well as stabilizer as reported by Lee et al. [6]. The use of 
surfactants in the nanosuspension aids in decreasing the size of the drug 
particle. In Nanopure technology (PharmaSol GmbH, Germany), poorly 
water soluble drugs are transferred to drug nanocrystals via a high-
pressure homogenization process [7].  The nanosuspensions can be used 
as granulation fluid for further tablet production by very smart formula-
tion approach. The nanosuspension is admixed to binders and other 
excipients, and the granules are finally compressed into tablets [8]. In this 
study we have investigated the formulation technological process and 
different parameters influencing the performance of nanosuspension. 
The oral bioavailability of Lacidipine tablets containing nano crystals of 
Lacidipine was assessed using an animal model. 
 
Material and methods. Lacidipine was obtained as a gift sample from 
Unichem Laboratories Ltd, Mumbai. Hydroxy propyl cellulose-L was a 
kind gift of Aqualon, Signet, Mumbai. Cremophor EL andPEG 20000 was 
obtained as a gift sample from Sigma Aldrich, Mumbai. Dehydrated etha-
nol from Merck, Goa. Microcrystalline Cellulose and Lactose Monohy-
drate from, Signet Mumbai.  Butylated hydroxy toluene from Penta man-
ufacturing Co, Mumbai. Magnesium stearate was obtained as a gift sam-
ple from Ferro. Preparation of Lacidipine tablets using Nanopure® Tech-
nology. Hydro alcoholic dispersing solvent was taken in a SS vessel, and 
divided into two equal portions. To one portion surfactant and antioxi-
dant was added under stirring. The drug Lacidipine was added to the 
other portion under continuous stirring. Both of the portions were mixed 
under continuous stirring. The suspension was passed through high pres-
sure homogenizer (GEA Niro soavi, Model type NS1001L2K) to get nano 
sized meter nanosuspension. The nano sized suspension containing nano 
crystal of Lacidipine was used as a granulating solvent for further tablet 
production. The nano sized suspension was kept at a temperature range 
between 2 to 8 ºC by ice pack to prevent agglomeration of particles. The 
hold study was done on nano sized suspension for 72 hours. The initial 
particle size in the nanosuspension FL4 was found to be 293.7 nm and 
the size changes to 286.9 nm indicating that there is no significant change 
in the nano particle during the hold study. The base materials selected 
for the granulation process were microcrystalline cellulose, Lactose mon-
ohydrate, PVP K-25 and Crospovidone CL. The granules were dried fol-
lowed by lubrication with magnesium stearate. Finally the lubricated 
granules were compressed into tablets. The pictorial flow chart of the 
process is displayed in Figure 1, the qualitative and quantitative composi-
tion of Lacidipine is displayed in Table 1. Solubility studies. The solubility 
of Lacidipine was determined by mixing an excess quantity of the drug 
with approximately 2 ml of the solvent taken in a screw-capped bottle. 
The bottles were rotated on a rotary shaker (Dolphin, Mumbai) at 100 
rpm for 24 hrs at room temperature to attain equilibrium condition. Fou-
rier transforms infrared spectroscopy (FT-IR). Fourier transform infrared 
spectroscopy was analyzed by Shimadzu, Japan. The drug was weighed 
and mixed with previously dried potassium bromide KBr. The mixture 
was carefully grinded and the homogenous mixture was placed in an IR 
pellet die subjected to a pressure of 900 Mpa (9t*cm-2) for about 2 
minutes to form a disc. The spectral scanning was done in the range of 
4000 to 400 cm -1[9]. Differential scanning calorimetry (DSC). The differ-
ential scanning calorimeter was done to evaluate the compatibility study 
of drug Lacidipine with hydroxy propyl cellulose. The binary mixture of 
Lacidipine and hydroxy propyl cellulose were mixed in the ratio of 1:5 
which was subjected to DSC. The sample was heated from 0 to 230 °C at 
a heating rate of 10 °C/minute under argon atmosphere using a micro 
calorimeter (DuPont, USA). X-Ray diffraction. To confirm the physical 
state of the drug in the nanosuspension state, X-ray diffraction was done 
in an X-ray diffractometer (X’pert, Philips, the Netherlands). The result 
was observed with a Cu anode used at a voltage of 45 KV at 4Ma. The 
scan type was continuous and the scan start position was 2.012 to 38.27. 
The scan step time was 180 seconds. The scattered intensities were 
measured at ambient temperature and the results were recorded. In-
vitro drug release studies. The in vitro drug release from the Lacidipine 
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tablet 4 mg was carried out in USP II dissolution apparatus with auto 
sampler containing 500 ml of purified water for a time period of 1 hr. Due 
to its very low solubility nature of Lacidipine, surfactant i.e. 1% Polysorb-
ate 20 was added in the dissolution media to maintain the sink condition. 
Dissolution media was maintained at a temperature of 37±0.5 °C. The 
aliquots of 10 ml dissolution media were auto sampled at specified time 
points and replaced with fresh media immediately after sampling. Sam-
ples were analyzed for drug content by UV Visible spectroscopy at a max-
imum wavelength of 284 mm. Particle size and zeta potential. The Zeta 
potential and nano particle size distribution of Lacidipine were deter-
mined using photon correlation spectroscopy (Zetasizer Nano ZS, 
ZEN3600; Malvern Instruments, Malvern, UK). The zeta potential was 
measured using a disposable zeta cuvette and the particle size distribu-
tion analysis was performed at angle of 90° degrees at a temperature of 
25°C. The zeta potential was measured using a disposable zeta cuvette. 
Entrapment efficiency. Aliquots of quantity 2 ml of the freshly prepared 
nanosuspensions were centrifuged at 10,000 rpm for 10 min, and the 
amount of unincorporated drug was measured by UV analysis of the 
supernatant. The final supernatant was used to measure any un-
entrapped Lacidipine which might be precipitated in the system. 
 
EE % = (NL / TL)*100      [Equ 1]  
 
Where EE is for “Entrapment Efficiency” , NL is for “Nanoparticles Laci-
dipine”  and TL  is for “Total Lacidipine”. Moreover Nanoparticles Laci-
dipine  is  given by the difference  of TL and Lacidipine in supernatant. 
Morphology. The morphology of the Lacidipine nano particles (FL4) was 
analyzed using a Transmission Electron Microscope (TEM).  The Laci-
dipine nanosuspension droplet was floated on droplet on to the carbon 
coated grids on Para film so that the nano crystal of Lacidipine gets fully 
adsorbed on to the grid. The grid was then dried with filter paper and 
then dried for 10 minutes. Finally the grid was transferred on to a drop of 
the negative stain. The negative stain used in these experiments was 
Uranyl acetate (0.5%). The formulation FL4 was examined with a Jeol 
Electron microscope to confirm the morphology of Lacipdine. Animal 












































Sr.no.  Ingredients  Role  FL 1  FL 2  FL 3  FL4  
Unit  - - mg  mg  mg  mg  
Nanosuspension prepared by Niro Savi is further  used  as granulating media  
1 Lacidipine  API  4 4 4 4 
2 Cremophor ELP  Surfactant  - - - 10 
3 HPC-L  Stabilizer  20 - - 20 
4 PEG 20000  Stabilizer  - 20 - - 
5 Polyvinyl pyrollidone K-25  Stabilizer  - - 20 - 
6 Butylated Hydroxytoluene  Anti-oxidant  4 4 4 4 
7 Purified Water  Dispersion Vehicle  q.s.  q.s.  q.s.  q.s.  
8 Isopropyl Alcohol  Dispersion Vehicle  q.s.  q.s.  q.s.  q.s.  
Base Material for granulation  
9 Lactose Monohydrate 200M  Dilutent  150 150 150 140 
10 Microcrystalline Cellulose pH 101  Dilutent  46 46 46 46 
11 PVP K -25  Binder  6 6 6 6 
12 Crospovidone CL  Disintegrant  8 8 8 8 
Extragranular material  
13 Aerosil  Glidant  6 6 6 6 
14 Magnesium stearate  Lubricant  6 6 6 6 
- 250 250 250 250 Total tablet weight (mg)   
Table 1. Qualitative andQuantitative composition of Lacidipine Nanosuspension. 
Drug Nanosuspension 
(Lacidipine   + Cremophor ELP + 
Polymer+ Antioxidant + Water + 
Isopropanol) 
Comminution 
(Using Niro Savi  producing Nano 
crystal)  
Granulation using Drug Nanosus-
pension over  
(MCC+Lactose+PVP + Cro-
spovidone) 
Drying, Lubrication & Tableting 
Drug Nano crystal formulated into 
tablets 
    
Figure 1.  Process flow chart of Lacidipine nanosuspension processed into tablets using Nanopure® technique. 
Figure 2.  A) Bluish opalescence confirming the formation of Lacidipine 
nanosuspension B) Zeta size particle size distribution of Lacidipine nano-
suspension formulation (FL4). 
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care and handling. The experiments were carried out on New Zeeland 
White Rabbit of 4 months, of both sexes, weighing between 2.0 to 2.5 kg. 
They were provided from Sapience Bio-analytical Research Lab, Bhopal, 
(M.P.). The experiment was approved by the institutional ethics com-
mittee of Sapience Bio-analytical Research Lab and as per CPCSEA guide-
lines (approval no. 1413/PO/a/11/CPCSEA) under CPCSEA, India. The 
animals were acclimatized to the standard laboratory conditions in cross 
ventilated animal house at temperature 25±2°C relative humidity 44–56% 
and light and dark cycles of 12:12 hours, fed with standard pallet diet, 
green vegetables and  water ad libitum during experiment [10]. Formula-
tions were placed in plastic tube and this tube was attached to a water 
filled syringe. A wooden biting block with a central opening was placed 
between the upper and lower teeth of the rabbit and formulations con-
taining tube insert in central opening of wooden block. A cannula was 
inserted into the marginal ear vein for blood sampling and flushed with 
heparinized normal saline solution. Study design and Sample Processing. 
Six rabbits were randomly divided into 2 groups, 3 animals each. Groups 
1 received reference tablets (Motens® Tablets 4 mg from Boehringer 
Ingelhium, US) given po. 3.0mg/kg/day [10]. The Group 2 was subjected 
to test formulation product (FL4) containing the nanosuspension at the 
same dose of 3.0 mg/kg/day. Blood samples were taken from ear margin-
al vein of rabbits at pre-dosing and 0.25, 0.5, 0.75, 1.0, 1.25, 1.50, 1.75, 
2.0, 2.25, 2.50, 2.75, 3.0 , 4.0 , 6.0, 8.0, 12.0, 24.0, 36.0, 48.0 hr for both 
Groups 1 and 2. Data Analysis. The concentration in plasma of rabbits 
was measured and the PK parameters were calculated using Win-Nonlin-
Pro® software version 4.0.1 (Pharsight Corpo-ration, US) 12. The area 
under the plasma concentration curve from time zero to infinity (AUC 0-
∞), terminal half-life (t1/2), highest plasma concentration observed (Cmax), 
and time to Cmax(Tmax) for Lacidipine were determined. Chromatographic 
Condition. The estimation of Lacidipine from rabbit were prepared using 
Nifedipine as internal standard and finally extracting into absolute etha-
nol and n-hexane in the ratio of 3:97 solvent system. The resulting solu-
tion was centrifuged at 4000 rpm for 7 minutes. The supernatant layer 
was estimated by HPLC. The chromatographic condition was carried out 
on a stainless steel column (packed with cyanosilyl silica gel),  using a 
mixture of 3 volume of absolute ethanol and 97 volume of n-Hexane 
sonicated to degas as a mobile phase at a flow rate of 2.0 ml per minute. 
The pH was maintained at 4.0. The drug was monitored by UV detector at 
240 nm at a flow rate of 2.0 ml per minute with a total run time of 15 
minutes. This method is previously known method as reported by 
Ramesh et al. with minor modification [11]. 
 
Results and Discussion. Solubility studies. The solubility studies done for 
Lacidipine in different solvents resulted in a concentration of less than 10 
µg/ml. Lacidipine is practically insoluble in 0.1 N HCl, pH 4.5 and pH 6.8 
phosphate buffers. From the above study it can be concluded that Laci-
dipine is poorly soluble in aqueous media.  The solvent ideal for the de-
velopment of nanosuspension  using nano pure technique should be 
water immiscible, hence water and isopropyl alcohol was selected as the 
choice of solvents. Effect of Stabilizer. The particle size of Lacidipine in 
the nanosuspension was found to be dependent on stabilizer. The stabi-
lizers used in the formulation FL1, FL2 and FL3 differed primarily in both 
molecular weight and hydrophilicity. The Specific surface area of the 
polymer was found to be another crucial factor affecting the particle size 
of nanosuspension. The greater surface area enhances the polymer to 
better adsorb on the particle surface forming hydrodynamic boundary 
layer which helps in greater repulsion, steric hindrance and inhibit  crys-
tal growth and thus better stability of the nanosuspension. This finding is 
also in accordance to one of the study reported by Muller et al. [12]. The 
adsorption of the polymer is influenced by the higher molecular weight. 
Hydroxy propyl cellulose exhibited highest molecular weight value 
(MW=7,000–29,000) followed by polyvinyl pyrrolidone K25 (MW=28,000-
34,000) and polyethylene glycol (Average Mn is 20). The presence of 
ether and hydroxyl group of the hydroxy propyl cellulose forms strong 
adsorption with Lacidipine. Due to high molecular weight, specific surface 
energy and adsorption of hydroxy propyl cellulose, formulation FL1 was 
found to perform effective nano comminution. In formulation FL2 due to 
absence of any hydrophobic unit for adsorption in Polysorbate 80, the 
formulation was ineffective in nanosuspension. In formulation FL3 poly-
mer PVP proved to be a worst polymer stabilizer due to the presence of 
amide group.  The stabilizer used in the nanosuspension should have 
hydrophobic moiety so that there is increase reduction in change of  
Gibbs  free energy  ( ∆ G) , enhancing the  efficiency of formation of nano 
particles.  The effective nanometer size of Lacidipine in the nanosuspen-
sion slurry in different formulations can be arranged in the ascending 
order of PVP<PEG<HPC. The Zeta potential  tends to move towards great-
er negative value with decrease in the particle size. The Polydispersibility 
index and % transmittance of the formulation trial FL4 is better compared 
to other formulation trials. The drug content of all the formulations was 
found to be satisfactory in all the formulation trials. The comparison of 
the different stabilizer influencing the nanosuspension physiochemical 
parameters are tabulated in Table 2 and Table 3. Effect of Surfactant 
interaction. The additional use of surfactant regardless of cationic or 
anionic affects the particle size of the drug during nano comminution as 
reported by Park CH et al. [13]. By the results obtained from drug-
polymer interaction, HPC used in the formulation FL1 seems to be better 
stabilizer compared to PEG and povidone. Hence the formulation FL1 
with HPC along with surfactant Cremophor EL was evaluated in the sub-
sequent formulation trial FL4. The addition of surfactants appears to 
have synergistic effect in reducing the nanosuspension slurry to nano 
meter scale. The formulation FL4 showed a more pronounced reduction 
in PSD after addition of the Cremophor ELP. The Volume median diame-
ter ([v, 0.9]) was further reduced to 20 % after addition of surfactant. The 
formulation FL4 shows a bluish opalescence after passing through high 
pressure homogenizer indicating the formation of nanosuspension [14]. 
Particle size determination. Particle size distribution was carried out by 
Zeta Sizer. The average cycle maintained was 10 cycles in each of the 
formulation FL1 to FL4. It was observed that after 10 cycles, the particle 
size remains unchanged. The average particle sizes of the optimized for-
mulation FL 4 was found to be 293.7 nm and the particle size distribution 
remains unchanged after 10 cycles. The particle size distribution deter-
mined by Zeta sizer of the optimized nanosuspension in formulation FL4 
is represented in Figure 2. Fourier Transformed Infrared (FTIR) Spectro-
scopic Analysis. The chemical compatibility of Lacidipine with stabilizer 












































Batch No  Polydispersibility Index  Nano droplet size (nm)  Zeta Potential (mV)  Transmittance (%)  Entrapment efficiency *(%)  
FL1@  0.437  453.1  -75.4 98.9 98.8 
FL2  0.325  1518  -30.2 97.5 96.5 
FL3  0.278  2530  -16.5 96.9 97.3 
FL4 @  0.445  293.7  -80.4 99.2 99.1 
Table 2.   Influence  of different stabilizer in the characteristic property of Nano-suspension. * Value shown as the mean ±SEM.  @ Both of the formu-
lation trial differ in the absence / presence of surfactant (Cremophor EL). 
Batch No  
Initial particle size before 
homogenization  
After 5 cycles  After 10 cycles  After 15 cycles  After 20 cycles  
FL4  ~ 6000  nm  ~ 2000 nm  293.7  nm  292.6  nm  292.6  nm  
Batch No  
Nano Particle size 
(Initial) in  
Hold study particle size 
after 24 hours  
Hold study particle size 
after 72hours  
Stability after 3 Months 
40 °C /75 % RH  
Stability after 4 week 60 
°C  
FL4  293.7  nm  286.9  nm 286.9  nm 323.25  nm 311.24  nm 
Table 3.   Influence of  cycles and storage time on the particle size of  Nano-suspension in formulation batch  ( FL4 ). 
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HPC was confirmed by FTIR. The characteristic peak of Lacidipine showed 
a frequency band of 3347 cm-1, 2979 cm-1, 1675 cm-1 and 1629 cm-1. The 
group frequency of 3347 cm-1 and 2979 cm-1 corresponds to aliphatic N-H 
stretch while 1675 cm-1 and 1629 cm-1 corresponds to acetate C=0 
stretch; and C=C stretch respectively. The characteristic peaks of Laci-
dipine was found to be 3347 and 1675 cm-1.  The FTIR of formulation FL4 
showed significant changes in the frequency band of Lacidipine.  Both the 
characteristic peaks shifted from 3347 cm-1 to 3644 and 1675 cm-1  to 
1731 cm-1 respectively. The formulation FL4 shows a sharp peak at 744 
cm-1  indicating a mono substituted ring. The substitution may have been 
taken by the ether or hydroxyl group present in the hydroxy propyl cellu-
lose with the amine group present in the Lacidipine molecule. The mecha
-nism is not process degradation rather an hydroxyl bond with the high 
affinity amine group present in the Lacidipine. (See Supporting Material). 
Differential scanning calorimetric (DSC) studies. Compatibility study of 
Lacidipine and stabilizer hydroxyl propyl cellulose was studied with 
Differential Scanning Calorimeter. The thermogram of Lacidipine exhibit-
ed a sharp exothermic peak at 182.95 ºC for Lacidipine [2]. HPC Lapici-
dine sample exhibited an exothermic peak at 185.1 °C. It was observed 
that the onset temperature of Lacidipine in the mixture remains un-
changed indicating that the polymer is compatible with Lacidipine. The 
representative DSC of drug and the excipient are depicted in Figure 3. 
XRD. The diffractogram of pure lacidipine shows a characteristic peak at 
2θ equal to 7.3 degrees.  Lacidipine characteristic peak shifts indicating a 
change in solid state probably due to the thermal generated by attrition 
during the process of nano comminution.  The other probable reason 
may be of the interaction of Lacidipine and hydroxy propyl cellulose in 
molecular level during the comminution process.  The representative 
diffractogram are depicted in Figure 4. HPC and Cremophor do not exhib-
it any characteristic peaks. In vitro drug release. The reference product 
(4 mg Tablets), showed incomplete release of drug in 30 minutes. The 
drug released in 30 minutes was found to be less than 80 %. Whereas, 
the test formulation with polymer stabilizer HPC in batch No. FL1 showed 
complete release of drug in 30 minutes. The formulation with polymer 
HPC along with surfactant Cremophor (FL4)showed complete release of 
drug compared to reference product as well as FL1. The formulation with 
polymers such as PVP and PEG showed complete release of drug. It was 
observed that the release profile of the drug with the polymer PVP and 
PEG was found to be slower compared to formulation FL1 and FL4. The 
cumulative dug release Vs time was plotted which is depicted in Figure 5. 
In vivo study. The pharmacokinetic parameters for both reference and 
test formulation are summarized in Table 4. The mean plasma concentra-
tions vs. time graph are depicted in Figure 6. The In vivo bioavailability 
studies were performed to quantify the nanosuspension in test formula-
tion (T) after oral administration with the marketed reference tablet. 












































Figure 3. A) DSC thermogram of Lacidipine B) DSC thermogram of HPC 
and Lacidipine .  
Figure 4. Diffractogram of: A) Lacidipine B) Lacidipine with stabilizer hy-
droxy propyl cellulose C) Lacidipine before nano-comminution D) Laci-
dipine after passed through Niro soavi 1stcycle  E) Lacidipine after passed 
through Niro soavi 5th cycle F)  Lacidipine after passed Niro soavi 




Figure 5.  A) Photo obtained by optical microsocope revealing initial 
particle size of Lacipdine B) TEM of Lacidipine nano particle confirming 
the size of 200 nm C) In Vitro dissolution profile of Lacidipine formula-
tions. 
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From the Table 2 it can be inferred that the nanosuspension formulation 
FL4 showed maximum plasma concentration of 6.88 ng/ml while the 
reference formulation showed only 1.16ng/ml. The reference formula-
tion took 1.76 hours to reach maximum plasma concentration while the 
test formulation took 1.0 hours to reach maximum plasma concentration. 
The AUC 0-t and AUC o-∞ for test formulation were nearly 2 fold and 1.5 
times respectively than the reference formulation. From the above analy-
sis it is evident that the nanosuspension formulation FL4 showed im-
proved rate of drug release compared to the reference formulations. 
Since the rate limiting step in the absorption of Lacidipine is dissolution 
and the results from the study reveals that the nanoziation of drug in 
suspension is the rate limiting step which plays a major role for absorp-
tion. It can be explained that, following oral administration, nano-crystals 
disperse spontaneously in the GI due to the increased specific surface 
area where the active components are present in a solubilized form, and 
the nano-sized droplets size provides large specific surface area for drug 
absorption. Additionally high concentration of surfactant used in the 
nanosuspension may increase permeability of the lipophilic substance 
across the cell membrane, and lymphatic transport through the trans 
cellular pathway. 
 
Conclusions. A nanosuspension formulation of Lacidipine was formulated 
with optimized polymer and surfactant to improve the In Vitro and In 
Vivo performance of the drug. The important factors concluded in the 
preparation of Nanosuspension were specific surface area, molecular 
weight of the polymer, thermal behavior of the drug and the functional 
groups present in the drug and polymer. HPC proved to be the most 
successful stabilizer for nanosuspension compared to PEG 20000 and 
Polyvinyl pyrrolidone stabilizer’s studied. From the In vivo bioavailability 
studies performed on rabbits, it can be concluded that the nanosuspen-
sion prepared by high pressure homogenizer exhibits superior pharmaco-
kinetic parameters compared to reference oral conventional tablet.  
Lacidipine a cardiovascular drug in nanosuspension formulation can over-
come the limitation of low solubility, dissolution and bioavailability. 
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Parameters   
ln AUC0-t  ln AUC0-∞  Ln Cmax  Tmax  Half life  Kel  
hr*ng/mL  hr*ng/mL  ng/mL  hour  hour  1/hour  
Test  formulation (T)   
Mean  16.75 18.33 6.88 1.00 5.61 0.13 
CV %  74.01 72.23 64.72 19.58 110.20 71.22 
Reference  formulation ( R)   
Mean  8.35 11.85 1.16 1.76 10.54 0.07 
CV %  64.91 64.32 71.80 74.20 40.20 52.11 
Least Square Mean   
Test (T)  12.52 13.65 5.37 - - - 
Reference ( R)  5.84 8.84 0.84 - - - 
Least Mean square  46.67 64.70 15.75 - - - 
90 % CI (T/R)   
Upper Limit  33.78 50.18 12.25 - - - 
Lower Limit  64.47 83.42 20.32 - - - 
p-Value (ANOVA)  0.0012 0.01 0 - - - 
Table 4. Pharmacokinetic parameter of reference and test product. 
Figure 6. In Vivo mean plasma concentration vs. time graph for Laci-
dipine formulation. 
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